WO2017043616A1 - 炎症性呼吸器疾患の予防又は治療用医薬組成物 - Google Patents
炎症性呼吸器疾患の予防又は治療用医薬組成物 Download PDFInfo
- Publication number
- WO2017043616A1 WO2017043616A1 PCT/JP2016/076554 JP2016076554W WO2017043616A1 WO 2017043616 A1 WO2017043616 A1 WO 2017043616A1 JP 2016076554 W JP2016076554 W JP 2016076554W WO 2017043616 A1 WO2017043616 A1 WO 2017043616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pharmaceutical composition
- alkynyl
- active ingredient
- alkenyl
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an inflammatory respiratory disease such as pulmonary emphysema, bronchial asthma, and pulmonary fibrosis comprising an active compound (hereinafter referred to as “RXR agonist”) for a retinoid ⁇ ⁇ ⁇ X receptor () RXR).
- RXR agonist an active compound for a retinoid ⁇ ⁇ ⁇ X receptor () RXR.
- RXR agonist retinoid ⁇ ⁇ ⁇ X receptor
- Emphysema is an irreversible disease in which inflammatory cells such as neutrophils and alveolar macrophages are infiltrated locally in the lungs, and bronchiole fibrosis and alveoli are destroyed.
- Bronchial asthma is an increase in airway hyperresponsiveness, It is a chronic inflammatory disease of the respiratory tract characterized by stenosis.
- Pulmonary fibrosis is a progressive refractory disease in which the repair function works abnormally in the alveolar epithelial disorder and fibrosis occurs in the lung stroma.
- bronchodilators such as long-acting anticholinergic agents that are inhaled and inhaled long-acting ⁇ 2-stimulants are used, but they are only symptomatic and the basic therapeutic agents have not yet been established. Absent.
- uncontrollable asthma and death from asthma may be caused by optimal treatment with inhaled steroids and inhaled long-acting ⁇ 2-stimulants, leukotriene receptor antagonists, oral steroids, etc. Many still exist.
- no effective therapeutic agent for pulmonary fibrosis has been developed so far.
- Retinoid X receptor is a nuclear receptor that is a type of transcription factor that regulates DNA transcription and regulates transcription in a ligand-dependent manner.
- RXR is involved in gene expression and is a homodimer or other nuclear receptor, peroxisome proliferator-responsive receptor ⁇ (PPAR- ⁇ ), liver X receptor (LXR), retinoid receptor (RAR), vitamins It forms a heterodimer with D receptor (VDR), NR4, etc. and exerts its action.
- RXR full agonists have been reported to be effective in diabetes and inflammatory diseases in animal experiments. However, no reports of airway inflammation have been made.
- the activation of the RXR heterodimer by the RXR agonist produces a difference depending on the structure of the RXR agonist. Therefore, the RXR heterodimer activation ability may be different for each RXR partial agonist, and it is necessary to examine the efficacy of each compound.
- RXR agonist NEt-3IB has been found to reduce triglyceride elevation and the like as compared to known RXR full agonists (see, for example, Patent Document 1).
- the structural formula of RXR agonist NEt-3IB is as shown in formula (5).
- An object of the present invention is to provide a pharmaceutical composition using, as an active ingredient, a compound capable of preventing or treating inflammatory respiratory diseases by an action mechanism different from that of conventional methods.
- the present invention is a pharmaceutical composition for the prevention or treatment of inflammatory respiratory diseases comprising an RXR agonist as an active ingredient.
- the pharmaceutical composition comprising an RXR agonist, which is a compound represented by the following formula (1) or the following formula (2), as an active ingredient.
- D is selected from CMe 2 , N methyl, N ethyl or N isopropyl;
- R 1 is selected from a methyl group, a hydroxy group, a methoxy group or an ethoxy group;
- R 2 is selected from H, a methyl group or an ethyl group;
- X is, N, is selected from CH or C-CF 3;
- Y and Z are selected from N or CH.
- R 3 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl and aryl groups
- R 4 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl and alkoxy groups
- W is selected from NR 5 or CR 5 2
- R 5 is selected from hydrogen, straight or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl and aryl groups
- X 1 and Y 1 are selected from CH or N
- X 2 and Y 2 are selected from CH, CR 6 or N
- R 6 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl, alkoxy, halogen, nitro and amino groups
- Z 1 is selected directly or from a carboxyl
- the RXR agonist that is the compound represented by the formula (1) is preferably used as an active ingredient
- the RXR agonist that is a compound represented by the following formula (3) is particularly preferably used as an active ingredient.
- RXR agonist which is a compound represented by the formula (2)
- RXR agonist which is a compound represented by the following formula (4)
- a preferred embodiment of the present invention is a pharmaceutical composition for preventing or treating emphysema.
- Another preferred embodiment of the present invention is a pharmaceutical composition for preventing or treating bronchial asthma.
- COPD pulmonary emphysema / chronic bronchitis
- bronchial asthma bronchial asthma COPD combined syndrome
- pulmonary fibrosis pulmonary fibrosis
- eosinophilic polyangiogenic granulomatosis cystic fibrosis
- acute bronchitis acute pharynx
- inflammatory respiratory diseases such as inflammation, acute laryngitis, acute epiglottitis, acute upper respiratory tract inflammation such as acute tonsillitis.
- the pharmaceutical composition of the present invention is a composition for preventing or treating inflammatory respiratory diseases, and comprises an RXR agonist as an active ingredient.
- the pharmaceutical composition comprises an RXR agonist, which is a compound represented by the following formula (1) or the following formula (2), as an active ingredient.
- RXR agonist which is a compound represented by the following formula (1) or the following formula (2), as an active ingredient.
- D is selected from CMe 2 , N methyl, N ethyl or N isopropyl;
- R 1 is selected from a methyl group, a hydroxy group, a methoxy group or an ethoxy group;
- R 2 is selected from H, a methyl group or an ethyl group;
- X is, N, is selected from CH or C-CF 3;
- Y and Z are selected from N or CH.
- R 3 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl and aryl groups
- R 4 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl groups, alkenyl groups, alkynyl groups, aryl groups and alkoxy groups
- W is selected from NR 5 or CR 5 2
- R 5 is selected from hydrogen, straight or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl and aryl groups
- X 1 and Y 1 are selected from CH or N
- X 2 and Y 2 are selected from CH, CR 6 or N
- R 6 is selected from the group consisting of linear or branched, unsubstituted or substituted alkyl, alkenyl, alkynyl, alkoxy, halogen, nitro and amino groups
- Z 1 is selected directly or from
- composition comprising as a component an RXR agonist that is a compound represented by the following formula (3) or formula (4).
- RXR agonist that is a compound represented by the following formula (3) or formula (4).
- a compound in which X in formula (3) is N may be referred to as “CBt-PMN”.
- the compound represented by the formula (4) may be referred to as “NEt-4IB”.
- the above compound may further be a pharmaceutically acceptable salt.
- the present invention includes those isomers and also includes solvation. Products, hydrates and crystals of various shapes.
- pharmaceutically acceptable salts include pharmacologically and pharmaceutically acceptable general salts. Specific examples of such salts are as follows.
- Base addition salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, Aliphatic amine salts such as triethanolamine salt and brocaine salt; Aralkylamine salts such as N, N-dibenzylethylenediamine; Heterocyclic aromatic amine salts such as pyridine salt, picoline salt, quinoline salt and isoquinoline salt; Tetramethylammonium salt Quaternary ammonia such as salt, tetraethylammonium salt, benzyltrimethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium salt, methyltrioctylammonium salt, tetrabutylammonium salt Umushio
- Acid addition salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate; acetate, propionate, lactate, maleate, fumarate Acid salts, tartrate, malate, citrate, ascorbate, etc .; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate; asparagine And acidic amino acids such as acid salts and glutamates.
- inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate; acetate, propionate, lactate, maleate, fumarate Acid salts, tartrate, malate, citrate, ascorbate, etc .
- sulfonates such as methanesulfonate, isethionate
- Alkyl group means a linear or branched alkyl group having 1 to 20 carbon atoms, preferably 1 to 10 carbon atoms.
- it is an alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n -Pentyl group, isopentyl group, neopentyl group, tert-pentyl group, n-hexyl group, isohexyl group.
- Alkenyl group means a linear or branched alkenyl group having 2 to 20 carbon atoms, preferably 2 to 8 carbon atoms, having one or more double bonds to the above “alkyl group”. Examples thereof include vinyl group, 1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1,3-butadienyl group, 3-methyl-2-butenyl group and the like. .
- Aryl group means monocyclic aromatic hydrocarbon group (phenyl group) and polycyclic aromatic hydrocarbon group (for example, 1-naphthyl group, 2-naphthyl group, 1-anthryl group, 2-anthryl group, 9- Anthryl group, 1-phenanthryl group, 2-phenanthryl group, 3-phenanthryl group, 4-phenanthryl group, 9-phenanthryl group and the like.
- a phenyl group or a naphthyl group (1-naphthyl group, 2-naphthyl group) is used.
- alkynyl group means an alkynyl group having 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms, having one or more triple bonds in the alkyl group, and examples thereof include an ethynyl group, a 1-propynyl group, Examples include 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group and the like.
- alkoxy group means a linear or branched (chain) alkoxy group having 1 to 20 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, Examples include sec-butoxy group, tert-butoxy group, pentyloxy group, hexyloxy group, octadecanoxy group, allyloxy group and the like.
- a linear or branched lower alkoxy group having 1 to 6 carbon atoms is preferred.
- “Acyl group” means an alkanoyl group, an aroyl group, and the like.
- alkanoyl group include alkanoyl groups having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms (formyl group, acetyl group, trifluoroacetyl group, propionyl group, butyryl group, etc.).
- aroyl group include an aroyl group having 7 to 15 carbon atoms, and specific examples include a benzoyl group and a naphthoyl group.
- the above compound has partial agonist activity for RXR. Since RXR is a nuclear receptor involved in DNA transcription, the above compounds can also be called transcriptional regulatory compounds. As used herein, the term “modulation” or similar terms should be interpreted in the broadest sense, including enhancement or suppression of action. Whether the above-mentioned compound has an enhancing action or an inhibiting action can be easily assayed according to the method specifically shown in the following examples.
- the dosage is not particularly limited.
- the above compound is used in combination to regulate the action of retinoid, or when the drug of the present invention is administered to regulate the action of retinoic acid already present in the living body without using a medicine containing retinoid, etc.
- an appropriate dose can be easily selected.
- the active ingredient can be used in the range of about 0.01 to 1000 mg per adult day.
- the composition of the present invention can be administered either during the retinoid administration period and / or before or after that period. Is possible.
- one or more substances selected from the above compounds may be administered as they are, but preferably one or more of the above compounds are used. It is preferably administered as an oral or parenteral pharmaceutical composition.
- Oral or parenteral pharmaceutical compositions can be prepared using pharmaceutical additives available to those skilled in the art, that is, pharmacologically and pharmaceutically acceptable carriers.
- one or more of the above-mentioned compounds can be blended with a drug that exhibits a therapeutic effect on inflammatory respiratory diseases and used as a pharmaceutical composition in the form of a so-called combination. Specifically, it can be used in combination with an inhaled steroid drug, an inhaled long-acting ⁇ 2 agonist, a leukotriene receptor antagonist, an oral steroid drug, and the like.
- Examples of the pharmaceutical composition suitable for oral administration include tablets, capsules, powders, fine granules, granules, liquids, and syrups.
- the pharmaceutical composition suitable for parenteral administration includes For example, injections, drops, suppositories, inhalants, nasal drops, ointments, creams, patches and the like can be mentioned.
- Examples of pharmacologically and pharmaceutically acceptable carriers used in the production of the above pharmaceutical composition include, for example, excipients, disintegrating agents or disintegrating aids, binders, lubricants, coating agents, dyes, Diluents, bases, solubilizers or solubilizers, isotonic agents, pH adjusters, stabilizers, propellants, adhesives, and the like can be mentioned.
- compositions according to the present invention can be produced by appropriately modifying or altering the starting materials and reagents used in the process for producing the compound which is the active ingredient of the present invention, and the reaction conditions. .
- the manufacturing method of the compound which is a composition of this invention is not limited to what was specifically demonstrated by the Example.
- Example 1 ⁇ Creation of pulmonary emphysema mice and evaluation of drug efficacy> Mice with emphysema were prepared by the following procedure and evaluated for drug efficacy.
- FIG. 1 is a graph of static lung compliance evaluation of pulmonary emphysema model mice at the time of CBt-PMN administration.
- FIG. 2 is a graph of static lung compliance evaluation of pulmonary emphysema model mice at the time of NEt-4IB administration.
- CBt-PMN and NEt-4IB which are RXR partial agonists.
- the improvement effect was slightly larger in the CBt-PMN administration group than in the NEt-4IB administration group.
- FIG. 3 is a graph of the number of cells in the cell fraction of bronchoalveolar lavage fluid of emphysema model mice.
- bronchoalveolar lavage was performed on mice 4 days after elastase administration under endotracheal intubation, and the cell fraction of bronchoalveolar lavage was evaluated.
- the RXR partial agonist NEt-4IB administration group showed an inhibitory effect on the total cell count and neutrophil count.
- the RXR partial agonist NEt-4IB administration group showed a significant decrease compared to the drug non-administration group, and the effect was more significant than the RXR full agonist bexarotene.
- FIG. 4 is a graph evaluating the average alveolar distance in the lung tissue of pulmonary emphysema model mice at the time of CBt-PMN administration.
- FIG. 5 is a graph showing an evaluation of the average alveolar distance in the lung tissue of pulmonary emphysema model mice upon administration of NEt-4IB. Lung tissue was fixed with formalin and stained with HE, and the average alveolar wall was measured for evaluation of emphysema. Compared to the non-treated group, RXR partial agonists such as CBt-PMN and NEt-4IB were administered to improve emphysematous changes.
- FIG. 6 shows a photograph of HE-stained images of lung tissue of emphysema model mice.
- PPE / Vehicle the alveolar space expanded compared to the non-disease-inducing group (PBS / vehicle).
- PBS / vehicle the non-disease-inducing group
- Example 2 ⁇ Creation of bronchial asthma mice and evaluation of drug efficacy> Bronchial asthma mice were prepared by the following procedure, and drug efficacy was evaluated by the following procedure.
- Airway hypersensitivity was measured for evaluation of airway stenosis.
- Airway hypersensitivity was measured using a respiratory function measuring device (Flexivent, SIREQ) for mice that were endotracheally intubated 48 hours after the final exposure of OVA inhalation. Airway hypersensitivity was induced by inhalation of mesacolin.
- SIREQ respiratory function measuring device
- the mice were euthanized by extravasation and bronchoalveolar lavage was performed. Thereafter, lung tissue was removed and airway tissue was evaluated.
- FIG. 7 is a graph of pulmonary airway hypersensitivity evaluation in bronchial asthma model mice.
- airway resistance increased with increasing inhalation concentration of methacholine.
- the RXR partial agonist administration group indicated by the black triangle ( ⁇ ) showed a significant improvement effect on airway hypersensitivity.
- FIG. 8 is a graph of the number of cells in the cell fraction of bronchoalveolar lavage fluid from a bronchial asthma model mouse. Compared with the non-treated group, the RXR partial agonist NEt-4IB administration group showed an inhibitory effect on the total cell number, lymphocyte count, and eosinophil count.
- FIG. 9 is a photograph of HE-stained images of lung tissue of a bronchial asthma model mouse.
- the lung tissue is HE-stained after formalin fixation.
- OVA inflammatory cell infiltration centered on eosinophils was observed around the vascular airways in the pulmonary pathological tissue after inhalation exposure to OVA.
- the RXR partial agonist NEt-4IB administration group showed an improvement effect of local inflammatory cell infiltration in the RXR partial agonist NEt-4IB administration group.
- FIG. 10 is a graph showing the measurement results of cytokines (IL-5, IL-13) in the supernatant of bronchoalveolar lavage fluid of a bronchial asthma model mouse.
- cytokines IL-5, IL-13
- the supernatant in the bronchoalveolar lavage fluid was collected and cytokines were measured by ELISA.
- the inhibitory effect of IL-5 and IL-13, which are Th2 cytokines was observed in the RXR partial agonist NEt-4IB administration group.
- RXR partial agonists CBt-PMN and NEt-4IB showed a remarkable anti-inflammatory effect in the emphysema model or bronchial asthma model by repeated oral administration.
- the composition of the present invention can be expected to act as an active ingredient for the prevention and treatment of inflammatory respiratory diseases, and can provide a useful medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
R1は、メチル基、ヒドロキシ基、メトキシ基又はエトキシ基から選択され;
R2は、H、メチル基又はエチル基から選択され;
Xは、N、CH又はC-CF3から選択され;
Y,Zは、N又はCHから選択される。]
R4は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アリール基及びアルコキシ基からなる群から選択され;
Wは、NR5又はCR5 2から選択され;
R5は水素、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基及びアリール基から選択され;
X1,Y1は、CH又はNから選択され;
X2,Y2は、CH、CR6又はNから選択され;
R6は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アルコキシ基、ハロゲン、ニトロ基及びアミノ基からなる群から選択され;
Z1は、直接、又はアルキレン基、アルケニレン基及びアルキニレン基からなる群から選択される連結基を介したカルボキシル基、カルボン酸エステル又はヒドロキサム酸から選択される。]
R1は、メチル基、ヒドロキシ基、メトキシ基又はエトキシ基から選択され;
R2は、H、メチル基又はエチル基から選択され;
Xは、N、CH又はC-CF3から選択され;
Y,Zは、N又はCHから選択される。]
R4は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アリール基及びアルコキシ基、からなる群から選択され;
Wは、NR5又はCR5 2から選択され;
R5は水素、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基及びアリール基から選択され;
X1,Y1は、CH又はNから選択され;
X2,Y2は、CH、CR6又はNから選択され;
R6は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アルコキシ基、ハロゲン、ニトロ基及びアミノ基からなる群から選択され;
Z1は、直接、又はアルキレン基、アルケニレン基及びアルキニレン基からなる群から選択される連結基を介したカルボキシル基、カルボン酸エステル、又はヒドロキサム酸から選択される。]
<肺気腫マウスの作成、薬効評価>
肺気腫マウスを以下の手順で作成し、薬効評価を行った。
BALB/c雌性マウスにペントバルビタール又はイソフルランの投与による麻酔下で気道内に豚膵エラスターゼの投与を行い(day 0)肺気腫モデルを作成した。
[手順2]
Day -4からRXRパーシャルアゴニストである、CBt-PMN(式(3)で示される化合物)、及びNEt-4IB(式(4)で示される化合物)を配合した飼料を与えた。また、対照として既存薬であるRXRフルアゴニストのベキサロテン(bexarotene)を配合した飼料を与えた。
[手順3]
Day 4及びday 14に再びペントバルビタール又はキシラジン・ケタミンの投与による麻酔下で気管切開後、気管内チューブを挿入し、呼吸機能測定装置(Flexiware, SIREQ社)を用いて気腫性変化の評価のために静肺コンプライアンスの測定を行った。静肺コンプライアンスは肺組織の伸びやすさを表しているが、肺胞域の組織破壊を伴う疾患である肺気腫では静肺コンプライアンスが上昇する。
[手順4]
手順3の後、マウスを溢血安楽死させ、気管支肺胞洗浄を行った後に、肺組織を取り出し、肺気腫の評価を行った。
[手順5]
非治療群として、通常の飼料を与えた群も同様に肺気腫を惹起させ、静肺コンプライアンスの測定および、気腫性変化の評価を行った。
[手順6]
得られたデータについてAnovaの有意差検定を行い、非治療非肺気腫群に対しp<0.05を*で示した。また、非治療肺気腫群に対しP<0.05を#で示した。
<気管支喘息マウスの作成、薬効評価>
気管支喘息マウスを以下の手順で作成し、下記の手順で薬効評価を行った。
BALB/c雌性マウスに卵白アルブミン(OVA)の腹腔内投与(20 g of OVA emulsified in 2.25 mg aluminum hydroxide in a total volume of 100 μL)による全身感作をday 0とday 14に施行後、超音波ネブライザーによるOVA吸入曝露(20分間を3日:day 28-30)を行い、喘息反応を惹起させた。
[手順2]
Day 25からRXRアゴニスト(NEt-4IB)を配合した飼料を与えた。Day 32にペントバルビタール投与による麻酔下にて気管切開を施行し、気管内にチューブを挿入した。呼吸機能測定装置に接続後、気道狭窄の評価のために気道過敏性(気道抵抗)を測定した。
[手順3]
気道過敏性は、OVA吸入最終暴露48時間後に気管内挿管したマウスに対して呼吸機能測定装置(Flexivent, SIREQ社)を用いて測定した。なお、気道過敏性はメサコリン吸入により惹起させた。
[手順4]
手順2の後、マウスを溢血安楽死させ、気管支肺胞洗浄を施行した。その後、肺組織を摘出し、気道組織の評価を行った。
[手順5]
非治療群として、通常の飼料を与えた群も同様に喘息反応を惹起させ、気道過敏性の測定及び気道炎症の評価を行った。
[手順6]
また非喘息コントロール群として、OVAによる感作をおこなわずにOVAの吸入曝露のみを行う2群(RXRアゴニスト配合飼料摂取群、通常飼料摂取群)の気道過敏性及び気道炎症の評価も同様に行った。
[手順7]
得られたデータについてAnovaの有意差検定を行い、非治療非喘息群に対しp<0.01を**、p<0.05を*で示した。また、非治療喘息群に対しP<0.05を#で示した。
Claims (8)
- RXRアゴニストを有効成分とする炎症性呼吸器疾患の予防又は治療用医薬組成物。
- 下記式(1)または下記式(2)で示される化合物であるRXRアゴニストを有効成分とする、請求項1に記載の医薬組成物。
R1は、メチル基、ヒドロキシ基、メトキシ基又はエトキシ基から選択され;
R2は、H、メチル基又はエチル基から選択され;
Xは、N、CH又はC-CF3から選択され;
Y,Zは、N又はCHから選択される。]
R4は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アリール基及びアルコキシ基からなる群から選択され;
Wは、NR5又はCR5 2から選択され;
R5は水素、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基及びアリール基から選択され;
X1,Y1は、CH又はNから選択され;
X2,Y2は、CH、CR6又はNから選択され;
R6は、直線若しくは分岐状の、非置換若しくは置換の、アルキル基、アルケニル基、アルキニル基、アルコキシ基、ハロゲン、ニトロ基及びアミノ基からなる群から選択され;
Z1は、直接、又はアルキレン基、アルケニレン基及びアルキニレン基からなる群から選択される連結基を介したカルボキシル基、カルボン酸エステル、又はヒドロキサム酸から選択される。] - 前記式(1)で示される化合物であるRXRアゴニストを有効成分とする、請求項2に記載の医薬組成物。
- 前記式(2)で示される化合物であるRXRアゴニストを有効成分とする、請求項2に記載の医薬組成物。
- 肺気腫の予防又は治療用医薬組成物である、請求項1~6のいずれかに記載の医薬組成物。
- 気管支喘息の予防又は治療用医薬組成物である、請求項1~6のいずれかに記載の医薬組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/772,901 US11026932B2 (en) | 2015-09-10 | 2016-09-09 | Medicinal composition for preventing or treating inflammatory respiratory disease |
CN201680052287.XA CN108025075B (zh) | 2015-09-10 | 2016-09-09 | 炎症性呼吸器官疾病的预防或治疗用医药组合物 |
EP16844477.6A EP3348279B1 (en) | 2015-09-10 | 2016-09-09 | Medicinal composition for preventing or treating inflammatory respiratory disease |
JP2017538532A JP6826731B2 (ja) | 2015-09-10 | 2016-09-09 | 炎症性呼吸器疾患の予防又は治療用医薬組成物 |
KR1020187007787A KR20180048726A (ko) | 2015-09-10 | 2016-09-09 | 염증성 호흡기 질환의 예방 또는 치료용 의약 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-178885 | 2015-09-10 | ||
JP2015178885 | 2015-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017043616A1 true WO2017043616A1 (ja) | 2017-03-16 |
Family
ID=58239955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/076554 WO2017043616A1 (ja) | 2015-09-10 | 2016-09-09 | 炎症性呼吸器疾患の予防又は治療用医薬組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11026932B2 (ja) |
EP (1) | EP3348279B1 (ja) |
JP (1) | JP6826731B2 (ja) |
KR (1) | KR20180048726A (ja) |
CN (1) | CN108025075B (ja) |
TW (1) | TWI645851B (ja) |
WO (1) | WO2017043616A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061233A2 (en) * | 1999-04-14 | 2000-10-19 | Allergan Sales, Inc. | Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist |
JP2003507465A (ja) * | 1999-08-25 | 2003-02-25 | エフ.ホフマン−ラ ロシュ アーゲー | Rar選択的レチノイドアゴニスト |
JP2007517037A (ja) * | 2003-12-30 | 2007-06-28 | アラーガン インコーポレイテッド | RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム |
WO2010041449A1 (ja) * | 2008-10-09 | 2010-04-15 | 国立大学法人 岡山大学 | Rxr作動性物質を有効成分とする抗アレルギー剤 |
JP2013177329A (ja) * | 2012-02-28 | 2013-09-09 | Okayama Univ | Rxrパーシャルアゴニスト |
JP2014076953A (ja) * | 2012-10-09 | 2014-05-01 | Okayama Univ | レチノイドx受容体パーシャルアゴニスト化合物及びこのレチノイドx受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339107B1 (en) * | 2000-08-02 | 2002-01-15 | Syntex (U.S.A.) Llc | Methods for treatment of Emphysema using 13-cis retinoic acid |
ES2544482T3 (es) | 2007-02-27 | 2015-08-31 | National University Corporation Okayama University | Compuesto rexinoide que tiene un grupo alcoxi |
JP5255994B2 (ja) | 2008-11-04 | 2013-08-07 | 国立大学法人 岡山大学 | 核内受容体リガンド |
-
2016
- 2016-09-09 EP EP16844477.6A patent/EP3348279B1/en active Active
- 2016-09-09 KR KR1020187007787A patent/KR20180048726A/ko not_active Application Discontinuation
- 2016-09-09 US US15/772,901 patent/US11026932B2/en active Active
- 2016-09-09 WO PCT/JP2016/076554 patent/WO2017043616A1/ja active Application Filing
- 2016-09-09 CN CN201680052287.XA patent/CN108025075B/zh active Active
- 2016-09-09 TW TW105129369A patent/TWI645851B/zh active
- 2016-09-09 JP JP2017538532A patent/JP6826731B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061233A2 (en) * | 1999-04-14 | 2000-10-19 | Allergan Sales, Inc. | Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist |
JP2003507465A (ja) * | 1999-08-25 | 2003-02-25 | エフ.ホフマン−ラ ロシュ アーゲー | Rar選択的レチノイドアゴニスト |
JP2007517037A (ja) * | 2003-12-30 | 2007-06-28 | アラーガン インコーポレイテッド | RARγレチノイド受容体の選択的アゴニストとしての二置換カルコンオキシム |
WO2010041449A1 (ja) * | 2008-10-09 | 2010-04-15 | 国立大学法人 岡山大学 | Rxr作動性物質を有効成分とする抗アレルギー剤 |
JP2013177329A (ja) * | 2012-02-28 | 2013-09-09 | Okayama Univ | Rxrパーシャルアゴニスト |
JP2014076953A (ja) * | 2012-10-09 | 2014-05-01 | Okayama Univ | レチノイドx受容体パーシャルアゴニスト化合物及びこのレチノイドx受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3348279A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP3348279A1 (en) | 2018-07-18 |
US20200179353A1 (en) | 2020-06-11 |
TW201711681A (zh) | 2017-04-01 |
TWI645851B (zh) | 2019-01-01 |
KR20180048726A (ko) | 2018-05-10 |
US11026932B2 (en) | 2021-06-08 |
EP3348279A4 (en) | 2019-08-21 |
EP3348279B1 (en) | 2021-08-04 |
JPWO2017043616A1 (ja) | 2018-06-28 |
CN108025075B (zh) | 2020-09-22 |
JP6826731B2 (ja) | 2021-02-10 |
CN108025075A (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI735546B (zh) | 使用fxr促效劑之方法 | |
US11759467B2 (en) | Treatment | |
EP3419624B1 (en) | Methods for using fxr agonists | |
JP6523399B2 (ja) | 線維症の処置方法 | |
JP2018118971A (ja) | ウイルス疾患の処置におけるmek阻害物質 | |
EP1863522A2 (en) | Compounds having activity in correcting mutant-cftr processing and uses thereof | |
JP2006513165A (ja) | ムチン合成インヒビター | |
WO2021211858A1 (en) | Inhalable formulation of a solution containing tiotropium bromide and olodaterol | |
BR112015010842B1 (pt) | Uso da ciclesonida para o tratamento de doença das vias respiratórias em cavalos | |
TWI589305B (zh) | 用於經口投藥之包含安布索、左旋羥丙哌嗪及緩衝劑的液體調配物以及製備其之方法 | |
KR102647744B1 (ko) | 간질성 폐질환과 연관된 기침을 치료하는 토실산 서플라타스트 | |
WO2009051910A1 (en) | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof | |
WO2017043616A1 (ja) | 炎症性呼吸器疾患の予防又は治療用医薬組成物 | |
KR20230121890A (ko) | 섬유증 치료 방법 | |
TWI784232B (zh) | 胺烷基苯並硫氮呯衍生物之用途 | |
Yi-Fang et al. | Hypolipidemic effect of SIPI-7623, a derivative of an extract from oriental wormwood, through farnesoid X receptor antagonism | |
TW201542205A (zh) | 異常血脂症治療劑 | |
JP7125792B2 (ja) | 神経変性疾患の治療又は予防用Nurr1/RXR活性化剤 | |
WO2021211850A1 (en) | Inhalable formulation of a solution containing olodaterol | |
KR20180065223A (ko) | 천식의 치료 또는 완화용 약학 조성물 | |
WO2021211854A1 (en) | Inhalable formulation of a solution containing tiotropium bromide | |
JP2016504358A (ja) | オキシブチニンを投与するための方法および組成物 | |
RU2588133C2 (ru) | Ниациновые миметики и способ их использования | |
TW201306838A (zh) | 菸鹼酸模擬物及其使用方法 | |
JP2002338494A (ja) | ムチン合成インヒビター |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16844477 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017538532 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187007787 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016844477 Country of ref document: EP |